Market Overview

Alnylam Presents New Pre-clinical Data on ALN-AAT

Alnylam
Pharmaceuticals (NASDAQ: ALNY) announced today that it has presented new pre-clinical data
with ALN-AAT, an RNAi therapeutic targeting alpha-1 antitrypsin (AAT) in

Alnylam
Pharmaceuticals (NASDAQ: ALNY announced today that it has presented new pre-clinical data
with ALN-AAT, an RNAi therapeutic targeting alpha-1 antitrypsin (AAT) in
development for the treatment of liver disease associated with
AAT deficiency. These data
were presented in a poster entitled “Developing an RNAi Therapeutic for
Liver Disease Associated with Alpha-1-Antitrypsin Deficiency” at the 64th
Annual Meeting of the American Association for the Study of Liver
Diseases (AASLD, “The Liver Meeting”) held November 1 – 5, 2013 in
Washington, D.C. AAT deficiency liver disease is a rare genetic
disorder, with the most common mutation being in the “Z-allele,” which
results in the accumulation of the mutant AAT protein (Z-AAT)

See full press release

Posted-In: News Guidance FDA Global

 

Related Articles (ALNY)

Around the Web, We're Loving...

Get Benzinga's Newsletters